Outcomes of tuberculosis treatment depending on cyp2c19 genotype

P. B. Antonenko, V. I. Kresyun

Abstract


As proven earlier, in patients with tuberculosis (TB) the concentration of antituberculosis drugs like isoniazid and rifampicin may differ depending on polymorphism of CYP2C19. The aim of the research was to determine the peculiarities of the pulmonary TB course and its outcome after the in-patient treatment depending on CYP2C19 genotype of the patients. The analysis of medical cards from 83 patients with the primary pulmonary tuberculosis at the end of the in-patient treatment in Odessa regional TB dispensary was conducted in 2012 with consideration of CYP2C19 genotype. At the beginning of the treatment the processes of disintegration were 3 times less in patients with *1/*1 genotype than in patients with *1/*2 genotype (10.3% versus 31.8%; P<0.05; χ2=5.40), and 6.5 times less than in individuals with *2/*2 genotype (10.3% versus 66.7%; P<0.05; χ2=7.94). At the end of the in-patient treatment the signs of pulmonary destruction were 6.5 times more common in individuals with *1/*1 genotype than in individuals with *1/*2 genotype (29.3 versus 4.5; Р<0.05; χ2=5.61). The signs of resorption and consolidation in the pulmonary tissue were observed in 74.1% of the patients with *1/*1 genotype, 95.5% of the patients with *1/*2 genotype and 66.7% of the patients with *2/*2 genotype. There were no significant differences between groups in relation to duration of the treatment and development of drug-resistance.


Keywords


tuberculosis; CYP2C19; treatment outcome

Full Text:

PDF

References


Антоненко П.Б., Кресюн В.Й. // Вісник наукових досліджень. – 2013. – №2. – С. 32-35.

Антоненко П.Б., Кресюн В.Й. // Одеський мед. журн. – 2013. – №5. – С. 16-20.

Мельник В.М., Новожилова І.О., Матусевич В.Г. та ін. // Укр. пульмонол. журн. – 2012. – №1. – С. 5-7.

Наказ МОЗ України №384 від 09.06.2006 р. «Про затвердження протоколу надання медичної допомоги хворим на туберкульоз»: Нормативні директивні правові документи. – К., 2006. – 87 с.

Фещенко Ю.І., Мельник В.М., Матусевич В.Г. та ін. // Укр. пульмонол. журн. – 2011. – №4. – С. 5-10.

Bertram G. Katzung’s Basic and Clinical Pharmacology. 12th Ed. – McGraw-Hill Education, 2012. – P. 842.

Dymova M.A., Liashenko O.O., Poteiko P.I. et al. // BMC Infect. Dis. – 2011. – №11. – Р. 77 (http://www. biomedcentral.com/1471-2334/11/77).

Falzon D., Jaramillo E., Schünemann H.J., Arentz M. // Eur. Respir. J. – 2011. – Vol. 38, №3. – P. 516-528.

Geetha Ramachandran, Soumya Swaminathan // Pharmacogenomics and Personalized Medicine. – 2012. – №5. – Р. 89-98.

Goldstein J.A., Blaisdell J. // Methods Enzymol. – 1996. – Vol. 272. – P. 210-218.

Mde J. Castillejos-López, García-Sancho M.C., Quiñones-Falconi F., Pérez-Padilla J.R. // Rev. Invest. Clin. – 2008. – Vol. 60, №1. – Р. 47-57.


GOST Style Citations






DOI: https://doi.org/10.24959/cphj.14.1300

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Klìn. farm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)